Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma

Emiddio Barletta, Francesco Fiore, Bruno Daniele, Alessandro Ottaiano, Roberto D'Angelo, Ettore Ferrari, Roberta Formato, Anna Tortoriello, Giacinto Turitto, Giovanni Salvatore Bruni, Sandro Pignata, Rosario Vincenzo Iaffaioli

Research output: Contribution to journalArticle

Abstract

The present study was conducted to evaluate activity and toxicity of the FLEC (folinic acid 100 mg/m2; 5-fluorouracil 1000 mg/m2; carboplatin 300 mg/m2; epirubicin 60 mg/m2) schedule as second-line treatment for progressive locally advanced or metastatic pancreatic cancer (LAMPC). FLEC was administered every 3 weeks with an angiographic catheter introduced into the tumor vascular bed. Thirty-two patients were enrolled. Twenty patients had a PS of 2. Twenty-five patients had metastatic disease to liver. Seven (21.9%) partial responses were observed (WHO criteria). Fifteen patients (46.9%) had stable disease and ten patients (31.2%) had progressive disease. The median OS from the diagnosis was 11.8 months. PS (p=0.0308) and pain (WHO scale, p=0.0222; analogic scale, p=0.0446) significantly improved after therapy. No patient discontinued treatment because of toxicity (NCI-CTC criteria). The current study shows that intraarterial chemotherapy is a good therapeutic option in second-line treatment of LAMPC.

Original languageEnglish
Pages (from-to)782-787
Number of pages6
JournalFrontiers in Bioscience
Volume11
Issue number1 P.447-888
Publication statusPublished - 2006

Fingerprint

Vascular Access Devices
Chemotherapy
Adenocarcinoma
Drug Therapy
Toxicity
Patient treatment
Epirubicin
Leucovorin
Catheters
Carboplatin
Pancreatic Neoplasms
Fluorouracil
Liver
Tumors
Therapeutics
Blood Vessels
Liver Diseases
Appointments and Schedules
Pain
1-(9-fluorenyl)ethyl chloroformate

Keywords

  • Intraarterial Chemotherapy
  • Pancreatic Adenocarcinoma
  • Second-Line Chemotherapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Barletta, E., Fiore, F., Daniele, B., Ottaiano, A., D'Angelo, R., Ferrari, E., ... Iaffaioli, R. V. (2006). Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma. Frontiers in Bioscience, 11(1 P.447-888), 782-787.

Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma. / Barletta, Emiddio; Fiore, Francesco; Daniele, Bruno; Ottaiano, Alessandro; D'Angelo, Roberto; Ferrari, Ettore; Formato, Roberta; Tortoriello, Anna; Turitto, Giacinto; Bruni, Giovanni Salvatore; Pignata, Sandro; Iaffaioli, Rosario Vincenzo.

In: Frontiers in Bioscience, Vol. 11, No. 1 P.447-888, 2006, p. 782-787.

Research output: Contribution to journalArticle

Barletta, E, Fiore, F, Daniele, B, Ottaiano, A, D'Angelo, R, Ferrari, E, Formato, R, Tortoriello, A, Turitto, G, Bruni, GS, Pignata, S & Iaffaioli, RV 2006, 'Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma', Frontiers in Bioscience, vol. 11, no. 1 P.447-888, pp. 782-787.
Barletta, Emiddio ; Fiore, Francesco ; Daniele, Bruno ; Ottaiano, Alessandro ; D'Angelo, Roberto ; Ferrari, Ettore ; Formato, Roberta ; Tortoriello, Anna ; Turitto, Giacinto ; Bruni, Giovanni Salvatore ; Pignata, Sandro ; Iaffaioli, Rosario Vincenzo. / Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma. In: Frontiers in Bioscience. 2006 ; Vol. 11, No. 1 P.447-888. pp. 782-787.
@article{fcc5e549f4674d8888043fcab0f06c9d,
title = "Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma",
abstract = "The present study was conducted to evaluate activity and toxicity of the FLEC (folinic acid 100 mg/m2; 5-fluorouracil 1000 mg/m2; carboplatin 300 mg/m2; epirubicin 60 mg/m2) schedule as second-line treatment for progressive locally advanced or metastatic pancreatic cancer (LAMPC). FLEC was administered every 3 weeks with an angiographic catheter introduced into the tumor vascular bed. Thirty-two patients were enrolled. Twenty patients had a PS of 2. Twenty-five patients had metastatic disease to liver. Seven (21.9{\%}) partial responses were observed (WHO criteria). Fifteen patients (46.9{\%}) had stable disease and ten patients (31.2{\%}) had progressive disease. The median OS from the diagnosis was 11.8 months. PS (p=0.0308) and pain (WHO scale, p=0.0222; analogic scale, p=0.0446) significantly improved after therapy. No patient discontinued treatment because of toxicity (NCI-CTC criteria). The current study shows that intraarterial chemotherapy is a good therapeutic option in second-line treatment of LAMPC.",
keywords = "Intraarterial Chemotherapy, Pancreatic Adenocarcinoma, Second-Line Chemotherapy",
author = "Emiddio Barletta and Francesco Fiore and Bruno Daniele and Alessandro Ottaiano and Roberto D'Angelo and Ettore Ferrari and Roberta Formato and Anna Tortoriello and Giacinto Turitto and Bruni, {Giovanni Salvatore} and Sandro Pignata and Iaffaioli, {Rosario Vincenzo}",
year = "2006",
language = "English",
volume = "11",
pages = "782--787",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "1 P.447-888",

}

TY - JOUR

T1 - Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma

AU - Barletta, Emiddio

AU - Fiore, Francesco

AU - Daniele, Bruno

AU - Ottaiano, Alessandro

AU - D'Angelo, Roberto

AU - Ferrari, Ettore

AU - Formato, Roberta

AU - Tortoriello, Anna

AU - Turitto, Giacinto

AU - Bruni, Giovanni Salvatore

AU - Pignata, Sandro

AU - Iaffaioli, Rosario Vincenzo

PY - 2006

Y1 - 2006

N2 - The present study was conducted to evaluate activity and toxicity of the FLEC (folinic acid 100 mg/m2; 5-fluorouracil 1000 mg/m2; carboplatin 300 mg/m2; epirubicin 60 mg/m2) schedule as second-line treatment for progressive locally advanced or metastatic pancreatic cancer (LAMPC). FLEC was administered every 3 weeks with an angiographic catheter introduced into the tumor vascular bed. Thirty-two patients were enrolled. Twenty patients had a PS of 2. Twenty-five patients had metastatic disease to liver. Seven (21.9%) partial responses were observed (WHO criteria). Fifteen patients (46.9%) had stable disease and ten patients (31.2%) had progressive disease. The median OS from the diagnosis was 11.8 months. PS (p=0.0308) and pain (WHO scale, p=0.0222; analogic scale, p=0.0446) significantly improved after therapy. No patient discontinued treatment because of toxicity (NCI-CTC criteria). The current study shows that intraarterial chemotherapy is a good therapeutic option in second-line treatment of LAMPC.

AB - The present study was conducted to evaluate activity and toxicity of the FLEC (folinic acid 100 mg/m2; 5-fluorouracil 1000 mg/m2; carboplatin 300 mg/m2; epirubicin 60 mg/m2) schedule as second-line treatment for progressive locally advanced or metastatic pancreatic cancer (LAMPC). FLEC was administered every 3 weeks with an angiographic catheter introduced into the tumor vascular bed. Thirty-two patients were enrolled. Twenty patients had a PS of 2. Twenty-five patients had metastatic disease to liver. Seven (21.9%) partial responses were observed (WHO criteria). Fifteen patients (46.9%) had stable disease and ten patients (31.2%) had progressive disease. The median OS from the diagnosis was 11.8 months. PS (p=0.0308) and pain (WHO scale, p=0.0222; analogic scale, p=0.0446) significantly improved after therapy. No patient discontinued treatment because of toxicity (NCI-CTC criteria). The current study shows that intraarterial chemotherapy is a good therapeutic option in second-line treatment of LAMPC.

KW - Intraarterial Chemotherapy

KW - Pancreatic Adenocarcinoma

KW - Second-Line Chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=32944476913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944476913&partnerID=8YFLogxK

M3 - Article

C2 - 16146770

AN - SCOPUS:32944476913

VL - 11

SP - 782

EP - 787

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 1 P.447-888

ER -